Drug formulation and delivery expert appointed as Catalent's Director of Global Scientific Affairs

Brings specialist knowledge of modified release technologies, polymer engineering and science, solids, liquids, semi-solids, nasal delivery, and the switch from prescription to OTC medications

Dr Reo brings to Catalent over 35 years of experience in the pharmaceutical industry, specializing in modified release technologies, polymer engineering and science, solids, liquids, semi-solids, nasal delivery, and the switch from prescription to OTC medications.

He joins Catalent from Bayer HealthCare, where he was Director, Rx-to-OTC Switch Science, and was responsible for leading the science disciplines and project team for the development of prescription to non-prescription classification change. Prior to this, Dr Reo worked in Rx-to-OTC roles both at Bayer, and previously, with Merck Consumer Healthcare.

Dr Reo began his career as Principal Scientist with McNeil Consumer Healthcare, before going on to work in senior scientific positions with Pfizer and Schering-Plough Healthcare, where he specialized in formulation design and development.

A graduate of Temple University in Philadelphia, he holds a doctorate in pharmaceutical sciences, and, for the past year, has chaired the Formulation Design & Development Section of the American Association of Pharmaceutical Scientists .

“We welcome Joe to Catalent in his new role, leading our scientific affairs team,” commented Julien Meissonnier, Vice President Science and Technology. “His proven expertise in drug delivery and experience in scientific partnerships will certainly be an asset to continue Catalent’s strategy of engaging with the external scientific community. Joe will play a key role in enhancing and evolving Catalent’s scientific offerings to deliver better outcomes to patients.”